EMA/107498/2018

European Medicines Agency decision

P/0062/2018

of 16 March 2018

on the acceptance of a modification of an agreed paediatric investigation plan for fidaxomicin (Dificlir), (EMEA-000636-PIP01-09-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0062/2018

of 16 March 2018

on the acceptance of a modification of an agreed paediatric investigation plan for fidaxomicin (Dificlir), (EMEA-000636-PIP01-09-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/98/2010 issued on 4 June 2010, the decision P/0313/2012 issued on 21 December 2012, the decision P/0063/2014 issued on 7 March 2014, the decision P/0264/2014 issued on 3 October 2014, the decision P/0098/2016 issued on 15 April 2016, the decision P/0058/2017 issued on 17 March 2017 and the decision P/0243/2017 issued on 4 September 2017,

Having regard to the application submitted by Astellas Pharma Europe B.V. on 6 November 2017 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 January 2018, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for fidaxomicin (Dificlir), film-coated tablet, granules for oral suspension, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Astellas Pharma Europe B.V., Sylviusweg 62, 2333 BE - Leiden, The Netherlands.

EMA/PDCO/734003/2017
London, 26 January 2018

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000636-PIP01-09-M07

Scope of the application

Active substance(s):

Fidaxomicin

Invented name:

Dificlir

Condition(s):

Treatment of enterocolitis caused by *Clostridium difficil*e

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Granules for oral suspension

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Astellas Pharma Europe B.V.

Information about the authorised medicinal product:

See Annex II

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5510
Send a question via our website www.ema.europa.eu/contact

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Astellas Pharma Europe B.V. submitted to the European Medicines Agency on 6 November 2017 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/98/2010 issued on 4 June 2010, the decision P/0313/2012 issued on 21 December 2012, the decision P/0063/2014 issued on 7 March 2014, the decision P/0264/2014 issued on 3 October 2014, the decision P/0098/2016 issued on 15 April 2016, the decision P/0058/2017 issued on 17 March 2017 and the decision P/0243/2017 issued on 4 September 2017.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 28 November 2017.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric Investigation Plan

2.1. Condition

Treatment of enterocolitis caused by *Clostridium difficile*

2.1.1. Indication(s) targeted by the PIP

Treatment of *Clostridium difficile* infections (CDI) also known as *Clostridium difficile* associated diarrhoea (CDAD)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Granules for oral suspension

Film-coated tablet

2.1.4. Measures

Area	Number of studies	Description
Quality-related studies	1	**Study 1** Development of an age-appropriate oral suspension formulation for use in children from birth to less than 18 years
Non-clinical studies	3	**Study 2** Pharmacokinetic evaluation of fidaxomicin oral suspension as compared to fidaxomicin oral tablets in adult beagle dogs **Study 3** Dose range-finding study for the evaluation of toxicokinetics and tolerability of fidaxomicin oral suspension in young beagle dogs **Study 4** Study for the evaluation of toxicity and toxicokinetics and effect on the developing gastrointestinal tract of fidaxomicin oral suspension in young beagle dogs

Clinical studies	2	**Study 5** Open-label study to determine the safety and pharmacokinetics of fidaxomicin oral suspension and tablets taken for ten days in paediatric patients aged 6 months to less than 18 years with *Clostridium difficile* Associated Disease (CDAD) **Study 6** Investigator-blind, randomised, parallel-group study to compare the safety and efficacy of fidaxomicin oral suspension and tablets taken q12h, with vancomycin oral solution and capsules taken q6h, for ten days in paediatric patients from birth to less than 18 years with *Clostridium difficile* Associated Disease (CDAD) **Study 7** This study was deleted in EMEA-000636-PIP01-09-M01. **Study 8** This study was deleted in EMEA-000636-PIP01-09-M03. **Study 9** This study was deleted in EMEA-000636-PIP01-09-M03.
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By March 2018
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of enterocolitis caused by *Clostridium difficile*

Authorised indication:

- Treatment of *Clostridium difficile* infections (CDI) also known as C. difficile associated diarrhoea (CDAD) in adults

Authorised pharmaceutical formulation(s):

Film-coated tablet

Route(s) of administration:

Oral use